Control of Liver Metastasis by Intrahepatic Chemotherapy with Angiotensin II

  • Yoshiaki Iwasaki
  • Kuniyoshi Arai
  • Manabu Ohashi
  • Toshio Takahashi
  • Masatsugu Kitamura


For cancer chemotherapy the sensitivity of the tumor to the used drug and the delivery of effective concentrations of that drug to the target tumor tissues are important factors. Angiotensin II-induced hypertension chemotherapy is an experimental drug delivery system for augmenting the anticancer effects, using functional differences in the microcirculation between tumor and normal tissue [1]. Blood flow in tumor tissue selectively increases when blood pressure is elevated by infusion of angiotensin II [2].


Gastric Cancer Liver Metastasis Hepatic Arterial Infusion Chemotherapy Synchronous Liver Metastasis Curative Gastrectomy 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Sato H, Sugiyama K, Hoshi M, et al (1995) Angiotensin II (AII) induced hypertension chemotherapy (IHC) for unresectable gastric cancer with reference to resection after down staging. World J Surg 19:836–842PubMedCrossRefGoogle Scholar
  2. 2.
    Sasaki Y, Imaoka S, Hasegawa Y, et al (1985) Change in distribution of hepatic blood flow induced by intra-arterial infusion of angiotensin II in human hepatic cancer. Cancer 55:311–316, 42PubMedCrossRefGoogle Scholar
  3. 3.
    Suzuki M, Hori K, Abe I, et al (1981) A new approach to cancer chemotherapy: selective enhancement of tumor blood flow with angiotensin II. J Natl Cancer Inst 67:663–669PubMedGoogle Scholar
  4. 4.
    Arai Y, Kamimura N, Suyama K (1982) A method to retain subcutaneously the catheter end connected to a new silicone reservoir in intraarterial infusion chemotherapy. Jpn J Cancer Chemother 9:1838–1842Google Scholar
  5. 5.
    Kikuchi S, Tsukamoto H, Mieno H, et al (1998) Results of resection of gastric cancer with distant metastases. Hepatogastroenterology 45:592–596PubMedGoogle Scholar
  6. 6.
    Nakajima T, Ota K, Ishihara S, et al (1993) Extended radical surgery for advanced gastric cancer. Surg Oncol Clin North Am 2:467–481Google Scholar
  7. 7.
    Miyazaki M, Itoh H, Nakagawa K, et al (1997) Hepatic resection of liver metastases from gastric carcinoma. Am J Gastroenterol 92:490–493PubMedGoogle Scholar
  8. 8.
    Elias D, Cavalcanti de Albuquerque A, Eggenspieler P, et al (1998) Resection of liver metastases from a non-colorectal primary: indications and results based on 147 monocentric patients. J Am Coll Surg 187:87–93CrossRefGoogle Scholar
  9. 9.
    Saito A, Korenaga D, Sakaguchi Y, et al (1998) Surgical treatment for gastric carcinomas with concomitant hepatic metastasis. Hepatogastroenterology 43:560–564Google Scholar
  10. 10.
    Colins JM (1984) Pharmacological rationale for regional drug delivery. J Clin Oncol 2:498–504Google Scholar
  11. 11.
    Buchwald H, Grage TB, Vassilopoulos PP, et al (1980) Intraarterial infusion chemotherapy for hepatic carcinoma using a totally implantable infusion pump. Cancer 45:866–869PubMedCrossRefGoogle Scholar
  12. 12.
    Lee Y-TM (1987) Regional infusion for metastatic liver tumors. In: Lokich JJ (ed) Cancer chemotherapy by infusion. Precept Press, Chicago, pp. 415–434CrossRefGoogle Scholar
  13. 13.
    Arai, Y., Endo, T., Sone, Y., et al (1994) Management of patients with unresectable liver metastases from colorectal and gastric cancer employing an implantable port system. Cancer Chemother Pharmacol 31:99–102CrossRefGoogle Scholar
  14. 14.
    Miyazaki M (1981) An evaluation of carcinostatic intraarterial infusion therapy in hepatic malignancy with special reference to effects of vasoactive drugs as combined with intrahepatic drug behavior. J Jpn Surg Soc 83:1295–1306Google Scholar
  15. 15.
    Satoh T, Katsumi M, Murai T, et al (1985) A noradrenaline-combined intra-arterial chemotherapy (anti-tumor effects when tumor vessels are in use). Jpn J Cancer Chemother 12:1975–1981Google Scholar
  16. 16.
    Sato H, Hoshi M, Wakui A (1986) Clinical study on angiotensin-induced hypertension chemotherapy. Jpn J Cancer Chemother 13:1439–1447Google Scholar
  17. 17.
    Kitamura M, Arai K, Iwasaki Y (1997) Arterial infusion chemotherapy for peritoneal and liver metastasis in gastric cancer. Jpn J Cancer Chemother 24:45–51Google Scholar
  18. 18.
    Noguchi S, Miyauchi K, Nishizawa Y, et al (1988) Augmentation of anticancer effect with angiotensin II in intraarterial infusion chemotherapy for gastric carcinoma. Cancer 62:467–473PubMedCrossRefGoogle Scholar
  19. 19.
    Hokita S, Takao S, Tokushige M, et al (1989) Two-route chemotherapy under AT-II induced hypertension using totally implanted injection port system for liver metastases derived from digestive cancers. Jpn J Cancer Chemother 16:2901–2904Google Scholar
  20. 20.
    Tsuji Y, Ohigashi H, Ishikawa O, et al (1996) A case of non-resectable pancreatic cancer surviving more than 4 years by intra-arterial infusion chemotherapy with angiotensin II. Jpn J Cancer Chemother 23:1617–1620Google Scholar
  21. 21.
    Sato T, Katsumi M, Murai T, et al (1985) A noradrenaline-combined intraarterial chemotherapy (anti-tumor effects when tumor vessels are in use). Jpn J Cancer Chemother 12:1975–1981Google Scholar
  22. 22.
    Arai K, Kitamura M, Iwasaki Y (1997) Extraarterial dislocation of indwelling catheter in hepatic arterial infusion chemotherapy special reference to tissue destruction by 5-fluorouracil. Jpn J Cancer Chemother 24:1832–1834Google Scholar

Copyright information

© Springer Japan 1999

Authors and Affiliations

  • Yoshiaki Iwasaki
    • 1
  • Kuniyoshi Arai
    • 1
  • Manabu Ohashi
    • 1
  • Toshio Takahashi
    • 1
  • Masatsugu Kitamura
    • 2
  1. 1.Department of SurgeryTokyo Metropolitan Komagome HospitalTokyoJapan
  2. 2.Department of SurgeryTokyo Metropolitan Bokutou HospitalTokyoJapan

Personalised recommendations